PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NVS vs. EQNR
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NVS and EQNR is 0.21, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

NVS vs. EQNR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Novartis AG (NVS) and Equinor ASA (EQNR). The values are adjusted to include any dividend payments, if applicable.

-10.00%-5.00%0.00%5.00%10.00%AugustSeptemberOctoberNovemberDecember2025
-8.10%
-1.81%
NVS
EQNR

Key characteristics

Sharpe Ratio

NVS:

-0.40

EQNR:

-0.10

Sortino Ratio

NVS:

-0.43

EQNR:

0.05

Omega Ratio

NVS:

0.94

EQNR:

1.01

Calmar Ratio

NVS:

-0.32

EQNR:

-0.08

Martin Ratio

NVS:

-0.75

EQNR:

-0.27

Ulcer Index

NVS:

8.61%

EQNR:

9.89%

Daily Std Dev

NVS:

16.26%

EQNR:

27.15%

Max Drawdown

NVS:

-41.72%

EQNR:

-66.92%

Current Drawdown

NVS:

-19.32%

EQNR:

-26.03%

Fundamentals

Market Cap

NVS:

$198.53B

EQNR:

$68.50B

EPS

NVS:

$5.72

EQNR:

$3.25

PE Ratio

NVS:

17.05

EQNR:

7.67

PEG Ratio

NVS:

2.90

EQNR:

3.57

Total Revenue (TTM)

NVS:

$37.51B

EQNR:

$75.97B

Gross Profit (TTM)

NVS:

$27.93B

EQNR:

$25.82B

EBITDA (TTM)

NVS:

$15.56B

EQNR:

$30.38B

Returns By Period

In the year-to-date period, NVS achieves a 0.23% return, which is significantly lower than EQNR's 5.19% return.


NVS

YTD

0.23%

1M

0.72%

6M

-8.10%

1Y

-6.27%

5Y*

5.71%

10Y*

5.41%

EQNR

YTD

5.19%

1M

13.89%

6M

-1.82%

1Y

-2.32%

5Y*

10.92%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NVS vs. EQNR — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NVS
The Risk-Adjusted Performance Rank of NVS is 2525
Overall Rank
The Sharpe Ratio Rank of NVS is 2525
Sharpe Ratio Rank
The Sortino Ratio Rank of NVS is 2121
Sortino Ratio Rank
The Omega Ratio Rank of NVS is 2121
Omega Ratio Rank
The Calmar Ratio Rank of NVS is 2727
Calmar Ratio Rank
The Martin Ratio Rank of NVS is 3030
Martin Ratio Rank

EQNR
The Risk-Adjusted Performance Rank of EQNR is 3838
Overall Rank
The Sharpe Ratio Rank of EQNR is 4141
Sharpe Ratio Rank
The Sortino Ratio Rank of EQNR is 3434
Sortino Ratio Rank
The Omega Ratio Rank of EQNR is 3333
Omega Ratio Rank
The Calmar Ratio Rank of EQNR is 4242
Calmar Ratio Rank
The Martin Ratio Rank of EQNR is 4141
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NVS vs. EQNR - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Novartis AG (NVS) and Equinor ASA (EQNR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for NVS, currently valued at -0.40, compared to the broader market-2.000.002.004.00-0.40-0.10
The chart of Sortino ratio for NVS, currently valued at -0.43, compared to the broader market-4.00-2.000.002.004.00-0.430.05
The chart of Omega ratio for NVS, currently valued at 0.94, compared to the broader market0.501.001.502.000.941.01
The chart of Calmar ratio for NVS, currently valued at -0.32, compared to the broader market0.002.004.006.00-0.32-0.08
The chart of Martin ratio for NVS, currently valued at -0.75, compared to the broader market-10.000.0010.0020.00-0.75-0.27
NVS
EQNR

The current NVS Sharpe Ratio is -0.40, which is lower than the EQNR Sharpe Ratio of -0.10. The chart below compares the historical Sharpe Ratios of NVS and EQNR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.001.502.00AugustSeptemberOctoberNovemberDecember2025
-0.40
-0.10
NVS
EQNR

Dividends

NVS vs. EQNR - Dividend Comparison

NVS's dividend yield for the trailing twelve months is around 3.87%, less than EQNR's 5.42% yield.


TTM20242023202220212020201920182017201620152014
NVS
Novartis AG
3.87%3.88%3.44%3.91%4.08%3.40%2.87%3.72%3.50%4.06%3.51%3.14%
EQNR
Equinor ASA
5.42%5.70%6.67%4.13%2.24%4.32%4.85%2.37%0.00%0.00%0.00%0.00%

Drawdowns

NVS vs. EQNR - Drawdown Comparison

The maximum NVS drawdown since its inception was -41.72%, smaller than the maximum EQNR drawdown of -66.92%. Use the drawdown chart below to compare losses from any high point for NVS and EQNR. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-19.32%
-26.03%
NVS
EQNR

Volatility

NVS vs. EQNR - Volatility Comparison

The current volatility for Novartis AG (NVS) is 4.22%, while Equinor ASA (EQNR) has a volatility of 8.65%. This indicates that NVS experiences smaller price fluctuations and is considered to be less risky than EQNR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%AugustSeptemberOctoberNovemberDecember2025
4.22%
8.65%
NVS
EQNR

Financials

NVS vs. EQNR - Financials Comparison

This section allows you to compare key financial metrics between Novartis AG and Equinor ASA. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab